This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Addus HomeCare (ADUS) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
Addus HomeCare (ADUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
U.S. Physical Therapy (USPH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 5.80% and 1.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Option Care (OPCH) Q4 Earnings Meet Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 0% and 0.80%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: U.S. Physical Therapy (USPH) Q4 Earnings Expected to Decline
by Zacks Equity Research
U.S. Physical Therapy (USPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DaVita HealthCare (DVA) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 12.22% and 1%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights DaVita, RadNet and U.S. Physical Therapy
by Zacks Equity Research
DaVita, RadNet and U.S. Physical Therapy are included in this blog.
3 Stocks to Bank on the Buoyant Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, RDNT and USPH are well-poised to gain from the prospects.
U.S. Physical Therapy (USPH) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
U.S. Physical Therapy (USPH) could produce exceptional returns because of its solid growth attributes.
Zacks.com featured highlights include: RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks
by Zacks Equity Research
RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks are highlighted in this Screen of the Week article.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
U.S. Physical Therapy (USPH) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 7.59% and 1.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Surges 3.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
U.S. Physical Therapy (USPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Earnings Preview: U.S. Physical Therapy (USPH) Q3 Earnings Expected to Decline
by Zacks Equity Research
U.S. Physical Therapy (USPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Encompass Health, RadNet, U.S. Physical Therapy and Quest Diagnostics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Encompass Health, RadNet, U.S. Physical Therapy and Quest Diagnostics
3 Top Stocks From the Buoyant Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. EHC, RDNT and USPH are well-poised to gain from the prospects.
U.S. Physical Therapy (USPH) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
U.S. Physical Therapy (USPH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
U.S. Physical Therapy (USPH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 29.73% and 1.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
U.S. Physical Therapy (USPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
U.S. Physical Therapy (USPH) Soars 17.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
U.S. Physical Therapy (USPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
3 Stocks to Bank on Rebounding Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well-poised to gain from the prospects.
U.S. Physical Therapy (USPH) Q1 Earnings Beat Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 16.36% and -0.75%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
U.S. Physical Therapy (USPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
U.S. Physical Therapy (USPH) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 30.12% and -0.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
U.S. Physical Therapy (USPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well positioned to gain from the prospects.